<DOC>
	<DOCNO>NCT02912715</DOCNO>
	<brief_summary>Prospective , multi-center , non-randomized clinical trial follow-up investigation 1 , 6 12 month . To confirm safety efficacy Passeo-18 Lux DCB new non-stented re-stenotic lesion superficial femoral artery ( SFA ) proximal popliteal artery ( PPA ) Chinese patient population .</brief_summary>
	<brief_title>Clinical Study Passeo-18 Lux Balloon Catheter Treatment Atherosclerotic Lesions ( BIOLUX-P IV CHINA )</brief_title>
	<detailed_description>A prospective , multi-centre , non-randomized clinical trial follow-up investigation 1 , 6 12 month . Approximately 250 subject enrol 15 Chinese study site . To confirm safety efficacy Passeo-18 Lux DCB interventional treatment new non-stented re-stenotic lesion superficial femoral artery ( SFA ) proximal popliteal artery ( PPA ) Chinese patient population .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age ≥ 18 year . Subject documented diagnosis peripheral arterial disease ( PAD ) classify Rutherford class 234 superficial femoral artery ( SFA ) and/or proximal popliteal artery ( PPA ) knee , locate arterial segment start least 1 cm beyond common femoral artery ( CFA ) bifurcation superficial profunda femoris artery ( proximal anatomical landmark ) distal P1 segment popliteal artery level proximal edge patella ( distal anatomical landmark ) . Subject able walk without assistive device ( e.g . walker , cane ) . Female subject childbearing potential must negative pregnancy test ≤ 7 day index procedure ; Both male female subject willing use reliable method birth control duration study must document adequate birth control . Signed dated Patient Informed Consent ( PIC ) form . Subject understands accepts duration study able willing comply requirement , include followup visit evaluation . Life expectancy , Investigator 's opinion , least 12 month . Target lesion consist de novo nonstented restenotic lesion ≥70 % diameter stenosis . Lesion length≤ 200 mm . Reference vessel diameter ≥ 2 mm ≤ 7 mm visual estimate . Subject ipsilateral/contralateral iliac disease require treatment index procedure include treatment successful ( angiographic evidence stenosis &lt; 30 % ) . Iliac disease treat firstly market device exclude drug elute stent drug coat balloon . Angiographic evidence adequate distal runoff foot ( least one native calf vessel [ posterior tibial , anterior tibial , peroneal artery ] patent , define &lt; 50 % diameter stenosis ) . Stroke STEMI within 3 month prior index procedure . Either local systemic thrombolytic therapy within 48 hour prior index procedure . Inability tolerate oral anticoagulation therapy ( blood thinner warfarin ) concomitant dual antiplatelet therapy ( DAPT ) . Known allergy sensitivity heparin , aspirin ( ASA ) , anticoagulant/antiplatelet therapy , and/or paclitaxel allergy contrast medium adequately pretreated prior index procedure . Breastfeeding woman . Chronic renal insufficiency serum creatinine &gt; 2.5 mg/dL within 14 day prior index procedure . White blood cell count ( WBC ) &lt; 3,000 cells/mm3 within 14 day prior index procedure . Platelet count &lt; 80,000 cells/mm3 &gt; 700,000 cells/mm3 within 14 day prior index procedure . Known suspect active systemic infection evidence WBC &gt; 14.0 ( 14000/mm3 ) within 14 day prior index procedure . Diagnosed bleeding diatheses hypercoagulable state . Subject enrol investigational device , drug biologic study . Any major ( e.g. , cardiac . peripheral , abdominal ) surgical procedure plan intervention perform within 30 day prior index procedure . Any major ( e.g. , cardiac . peripheral , abdominal ) elective procedure intervention within 30 day post index procedure . Target lesion know advance enrollment require treatment alternative therapy ( drugeluting ) stent , laser , atherectomy , cryoplasty , reentry device , cutting/scoring balloon , brachytherapy . Use embolic protection device also prohibit . Contralateral SFA/PPA disease require treatment set index procedure . Presence additional lesion target vessel require treatment index procedure meet inclusion criterion . Complete occlusion lesion &gt; 100mm . Target lesion instent postDCB restenosis previously treat bypass surgery . Lesion within adjacent aneurysm . Acute subacute thrombus target vessel . Angiographic evidence severe calcification . Failure successfully cross target lesion guide wire . Successful cross refers tip device extend beyond target lesion , occurrence flowlimiting dissection and/or perforation . Predilation result major ( ≥ Grade D ) flowlimiting dissection ( observed 2 orthogonal view ) residual stenosis &gt; 70 % translesional peak gradient &gt; 10mm Hg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>